1 | was | 817,822 |
2 | disorders.we | 2 |
3 | scleroembolisation | 2 |
4 | wias | 2 |
5 | 2-p | 1 |
6 | a/na | 1 |
7 | applied/not | 1 |
8 | b/hydrocortisone | 1 |
9 | blinding.we | 1 |
10 | c209 | 1 |
11 | confered | 1 |
12 | deter- | 1 |
13 | directly-as | 1 |
14 | doglioni | 1 |
15 | domains-were | 1 |
16 | horizons.we | 1 |
17 | losswe | 1 |
18 | m05-730 | 1 |
19 | mr29-12 | 1 |
20 | scorad.the | 1 |
21 | sites.dihydroartemisinin-piperaquine | 1 |
22 | survey-were | 1 |
23 | test-were | 1 |
24 | wew | 1 |
1 | 2-p | 1 |
2 | a/na | 1 |
3 | applied/not | 1 |
4 | b/hydrocortisone | 1 |
5 | blinding.we | 1 |
6 | c209 | 1 |
7 | confered | 1 |
8 | deter- | 1 |
9 | directly-as | 1 |
10 | disorders.we | 2 |
11 | doglioni | 1 |
12 | domains-were | 1 |
13 | horizons.we | 1 |
14 | losswe | 1 |
15 | m05-730 | 1 |
16 | mr29-12 | 1 |
17 | scleroembolisation | 2 |
18 | scorad.the | 1 |
19 | sites.dihydroartemisinin-piperaquine | 1 |
20 | survey-were | 1 |
21 | test-were | 1 |
22 | was | 817,822 |
23 | wew | 1 |
24 | wias | 2 |
1 | deter- | 1 |
2 | m05-730 | 1 |
3 | mr29-12 | 1 |
4 | c209 | 1 |
5 | a/na | 1 |
6 | confered | 1 |
7 | scorad.the | 1 |
8 | sites.dihydroartemisinin-piperaquine | 1 |
9 | b/hydrocortisone | 1 |
10 | domains-were | 1 |
11 | test-were | 1 |
12 | survey-were | 1 |
13 | blinding.we | 1 |
14 | horizons.we | 1 |
15 | disorders.we | 2 |
16 | losswe | 1 |
17 | doglioni | 1 |
18 | scleroembolisation | 2 |
19 | 2-p | 1 |
20 | directly-as | 1 |
21 | wias | 2 |
22 | was | 817,822 |
23 | applied/not | 1 |
24 | wew | 1 |